Grants and Contributions:
Title:
AAV Gene Therapy for the Treatment of Lipoprotein Lipase Deficiency
Agreement Number:
1014773
Agreement Value:
$366,946.00
Agreement Date:
Mar 14, 2024 - Mar 1, 2025
Description:
The project will lead to an improved and more cost-effective AAV-LPL gene therapy for the treatment of Lipoprotein Lipase (LPL) Deficiency. The previous limitations of the high costs of production of advanced biologics, such as Glybera, will be addressed through new cost-effective manufacturing in Canada. The project will develop a further optimized AAVbased gene therapy for the treatment of LPL Deficiency as a pilot demonstration of a cost-effective production strategy for new advanced gene therapeutics in Canada
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Vancouver, British Columbia, CA V6T 1Z3
Reference Number:
172-2023-2024-Q4-1014773
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
108161779
Recipient Type:
Academia
Recipient's Legal Name:
The University of British Columbia
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
NAICS Code:
541710 - R&D in the physical, engineering and life sciences